Nutraceutical Eriocitrin (Eriomin) Reduces Hyperglycemia by Increasing Glucagon-Like Peptide 1 and Downregulates Systemic Inflammation: A Crossover-Randomized Clinical Trial

Registro completo de metadados
MetadadosDescriçãoIdioma
Autor(es): dc.contributorUniversidade Estadual Paulista (UNESP)-
Autor(es): dc.creatorCesar, Thais Borges-
Autor(es): dc.creatorRamos, Fernanda Maria Manzini-
Autor(es): dc.creatorRibeiro, Carolina Barbosa-
Data de aceite: dc.date.accessioned2025-08-21T17:54:12Z-
Data de disponibilização: dc.date.available2025-08-21T17:54:12Z-
Data de envio: dc.date.issued2022-11-29-
Data de envio: dc.date.issued2022-11-29-
Data de envio: dc.date.issued2022-07-07-
Fonte completa do material: dc.identifierhttp://dx.doi.org/10.1089/jmf.2021.0181-
Fonte completa do material: dc.identifierhttp://hdl.handle.net/11449/237937-
Fonte: dc.identifier.urihttp://educapes.capes.gov.br/handle/11449/237937-
Descrição: dc.descriptionThis double-blind, randomized, placebo/controlled, crossover study evaluated the efficacy of Eriomin (R) in reducing hyperglycemia and improving diabetes-related biomarkers in individuals with hyperglycemia above 110 mg/dL (mean 123 +/- 18 mg/dL). Subjects (n = 30), divided into two groups (Eriomin or Placebo), who received a dose of 200 mg/d of the designated supplement for 12 weeks and, after a washout period of 2 weeks, switched to the other supplement in the following 12 weeks. Assessments of biochemical, metabolic, inflammatory, blood pressure, anthropometry, and dietary parameters were performed at the beginning and end of each intervention. Treatment with 200 mg/d of Eriomin significantly decreased blood glucose (-5%), homeostasis model assessment of insulin resistance (-11%), glucagon (-13%), interleukin-6 (-14%), tumor necrosis factor alpha (-20%), and alkaline phosphatase (-13%); but increased glucagon-like peptide 1 (GLP-1) by (17%) (P <= .05). At the end of the placebo period, there was a 13% increase in triglycerides (P <= .05). Other parameters evaluated did not change with Eriomin or placebo. In conclusion, intervention with Eriomin benefited the glycemic control of prediabetic and diabetic patients, with higher blood glucose levels, by increasing GLP-1 and decreasing systemic inflammation.-
Descrição: dc.descriptionIngredients by Nature (Montclair, CA, USA)-
Descrição: dc.descriptionSao Paulo State Univ UNESP, Sch Pharmaceut Sci, Lab Nutr, Araraquara, SP, Brazil-
Descrição: dc.descriptionSao Paulo State Univ UNESP, Sch Pharmaceut Sci, Lab Nutr, Rodovia Araraquara Jau km1, BR-14801902 Araraquara, SP, Brazil-
Descrição: dc.descriptionSao Paulo State Univ UNESP, Sch Pharmaceut Sci, Lab Nutr, Araraquara, SP, Brazil-
Descrição: dc.descriptionSao Paulo State Univ UNESP, Sch Pharmaceut Sci, Lab Nutr, Rodovia Araraquara Jau km1, BR-14801902 Araraquara, SP, Brazil-
Descrição: dc.descriptionIngredients by Nature (Montclair, CA, USA): 5045-
Formato: dc.format9-
Idioma: dc.languageen-
Publicador: dc.publisherMary Ann Liebert, Inc-
Relação: dc.relationJournal Of Medicinal Food-
???dc.source???: dc.sourceWeb of Science-
Palavras-chave: dc.subjectCitrus flavonoids-
Palavras-chave: dc.subjectEriocitrin-
Palavras-chave: dc.subjectGLP-1-
Palavras-chave: dc.subjectHyperglycemia-
Palavras-chave: dc.subjectNutraceutical-
Palavras-chave: dc.subjectSystemic inflammation-
Título: dc.titleNutraceutical Eriocitrin (Eriomin) Reduces Hyperglycemia by Increasing Glucagon-Like Peptide 1 and Downregulates Systemic Inflammation: A Crossover-Randomized Clinical Trial-
Tipo de arquivo: dc.typelivro digital-
Aparece nas coleções:Repositório Institucional - Unesp

Não existem arquivos associados a este item.